LungLife AI Inc on Monday said it has been chosen to participate in the US National Cancer Institute’s early detection research network, due to the strength of its technology.

LungLife is a California, US-based developer of clinical diagnostic solutions designed to aid the early detection of lung cancer. Using a minimally invasive blood draw, the company’s LungLB test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules.

The company will be one of two industry partners to participate in the Boston University and University of California Los Angeles lung cancer biomarker development laboratory.

The detection network is a division of the US National Cancer Institute, the federal government’s principal agency for cancer research & training.

LungLife’s clinical laboratory will operate as a biomarker reference laboratory, processing blood samples from the participating academic centres at UCLA and BU, where the LungLB test will be combined with imaging to assist their early detection research.

It is expected the blood samples will be collected over a number of years with progress and results presented to EDRN members at annual meetings.

LungLife said this would represent the first independent study of its testing technology LungLB.

Chief Executive Officer Paul Pagano said: ‘We are excited that LungLife will participate in such a prestigious national programme aimed at bringing early detection technology to the clinic, and we are delighted to work with UCLA and BU, two leading medical research institutions with teams that have been pushing the field forward to make important biomarkers available to patients.’

LungLife shares were trading 6.3% higher at 109.00 pence each in London on Monday morning.

Copyright 2022 Alliance News Limited. All Rights Reserved.